Asosiy kontentga oʻtish
Maqola

Pharmacological Correction of Cardiovascular Complications After Anthracycline-Based Therapy for Acute Leukemias

Zaripov AzizUltrasound Specialist, Samarkand Regional Multidisciplinary Medical CenterAmerova DilafruzTecher of the Department of Hematology, Samarkand State Medical UniversityRakhmanov AkbarAnesthesiologist-Resuscitator of Anesthesiology and Resuscitation Center, Samarkand Regional Multidisciplinary Medical Center
2025en
ABI

Annotatsiya

This study investigated the efficacy of medicinal correction strategies in mitigating cardiovascular complications induced by anthracycline therapy in patients diagnosed with acute leukemias. A retrospective cohort of 150 adult patients, treated with anthracycline-based chemotherapy between January 2015 and December 2025, who subsequently developed cardiac dysfunction (LVEF <50%, heart failure symptoms), was analyzed. Patients received guideline-directed medical therapies, primarily ACE inhibitors/ARBs and beta-blockers. The primary outcome, defined as improvement in LVEF by ≥10% or normalization to ≥50% at 12 months, was achieved by 68% of the cohort. Patients receiving ACE inhibitors/ARBs demonstrated a mean LVEF increase of 11.5%, significantly greater than the 9.8% observed in the beta-blocker group. Significant reductions in NT-proBNP levels () and improvements in NYHA functional class were also observed across the cohort, with 70% of patients improving from class III/IV to I/II. The incidence of major adverse cardiovascular events at 12 months was 18%, with adverse drug reactions occurring in 35% of patients, mostly mild and manageable. These findings suggest that timely medicinal intervention, particularly with ACE inhibitors/ARBs, can effectively improve cardiac function and clinical outcomes in patients with anthracycline-induced cardiotoxicity following acute leukemia treatment.

Hali tarjima qilinmagan

Iqtiboslar va manbalar

0 ta iqtibos0 ta foydalanilgan manba